# reload+after+2024-01-22 13:43:54.178611
address1§4 Stamford Plaza
address2§9th Floor 107 Elm Street
city§Stamford
state§CT
zip§06902
country§United States
phone§203 406 3700
website§https://www.caratherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.
fullTimeEmployees§106
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Christopher A. Posner', 'age': 53, 'title': 'President, CEO & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 1203759, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ryan D. Maynard', 'age': 54, 'title': 'Chief Financial Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 511699, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Joana  Goncalves M.D.', 'age': 49, 'title': 'Chief Medical Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 747251, 'exercisedValue': 0, 'unexercisedValue': 4666}, {'maxAge': 1, 'name': 'Dr. Derek T. Chalmers D.Sc., Ph.D.', 'age': 59, 'title': 'Co-Founder & Senior Advisor', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 580931, 'exercisedValue': 0, 'unexercisedValue': 1499180}, {'maxAge': 1, 'name': 'Dr. Frédérique  Menzaghi', 'age': 57, 'title': 'Chief Scientific Officer and Senior VP of R&D', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 826938, 'exercisedValue': 0, 'unexercisedValue': 530500}, {'maxAge': 1, 'name': 'Dr. Iris  Francesconi Ph.D.', 'title': 'Chief Strategy Officer & Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Scott M. Terrillion', 'age': 60, 'title': 'Chief Compliance Officer, General Counsel & Corporate Secretary', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 689629, 'exercisedValue': 0, 'unexercisedValue': 399600}, {'maxAge': 1, 'name': 'Mr. Eric  Vandal', 'title': 'Senior Vice President of Commercial', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Beth  Weinberg R.Ph.', 'title': 'Senior Vice President of Regulatory Affairs & QA', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Matthew  Murphy', 'title': 'Manager of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§4
boardRisk§4
compensationRisk§9
shareHolderRightsRisk§7
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.657
priceToSalesTrailing12Months§1.5744858
currency§USD
dateShortInterest§1702598400
forwardEps§-1.99
pegRatio§0.0
exchange§NGM
quoteType§EQUITY
shortName§Cara Therapeutics, Inc.
longName§Cara Therapeutics, Inc.
firstTradeDateEpochUtc§1391178600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§2959e4f9-c48b-308c-8431-9b84f96c60e5
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§1.0
targetMeanPrice§5.93
targetMedianPrice§6.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§7
quickRatio§3.683
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
